Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Phase 1

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: Venetoclax
Drug: Atezolizumab
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2020-06-09

Last Posted Date: 2021-11-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2

Registration Number: NCT04422210

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸
Emory University, Atlanta, Georgia, United States
🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark

and more 2 locations

First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

Phase 2

Completed

Conditions: Metastatic Breast Cancer
Advanced Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2020-05-29

Last Posted Date: 2024-06-04

Lead Sponsor: MedSIR

Target Recruit Count: 100

Registration Number: NCT04408118

Locations: 🇪🇸
MD Anderson Cancer Center, Madrid, Spain
🇮🇹
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy
🇫🇷
Hopital Europeen Georges Pompidou, Paris, France

and more 23 locations

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Phase 1

Terminated

Conditions: Castration-Resistant Prostatic Cancer

Interventions: Drug: Ipatasertib
Drug: Atezolizumab
Drug: Docetaxel

First Posted Date: 2020-05-27

Last Posted Date: 2023-10-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 6

Registration Number: NCT04404140

Locations: 🇫🇷
Gustave Roussy, Villejuif, France
🇪🇸
Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain
🇫🇷
Centre Val Aurelle Paul Lamarque; Radiotherapie, Montpellier, France

and more 6 locations

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Phase 2

Recruiting

Conditions: Extensive Stage Lung Small Cell Carcinoma

Interventions: Drug: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy

First Posted Date: 2020-05-27

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 138

Registration Number: NCT04402788

Locations: 🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
Hawaii Cancer Care - Westridge, 'Aiea, Hawaii, United States
🇺🇸
Pali Momi Medical Center, 'Aiea, Hawaii, United States

and more 384 locations

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Skin Neoplasm
Metastatic Malignant Skin Neoplasm

Interventions: Drug: Atezolizumab
Drug: Avelumab
Biological: Cemiplimab
Biological: Durvalumab
Biological: Nivolumab
Biological: Pembrolizumab
Other: Quality-of-Life Assessment
Other: Short-Term Fasting

First Posted Date: 2020-05-13

Last Posted Date: 2024-10-10

Lead Sponsor: University of Southern California

Target Recruit Count: 10

Registration Number: NCT04387084

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Extensive-stage Small Cell Lung Cancer

Interventions: Drug: Vorolanib
Drug: Atezolizumab

First Posted Date: 2020-05-04

Last Posted Date: 2024-05-16

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 11

Registration Number: NCT04373369

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Phase 2

Recruiting

Conditions: Lung Cancer
NSCLC

Interventions: Drug: Atezolizumab
Drug: Cisplatin
Drug: Docetaxel
Drug: Pemetrexed

First Posted Date: 2020-04-29

Last Posted Date: 2024-10-28

Lead Sponsor: Nasser Hanna

Target Recruit Count: 100

Registration Number: NCT04367311

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 7 locations

A Phase II Trial of PD-L1 Therapy Combined with Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Phase 2

Recruiting

Conditions: Clinical Stage III Cutaneous Melanoma AJCC V8
Stage IV Melanoma
Unresectable Stage III Cutaneous Melanoma
Unresectable Stage IV Cutaneous Melanoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2020-04-22

Last Posted Date: 2024-10-04

Lead Sponsor: Elizabeth Buchbinder, MD

Target Recruit Count: 30

Registration Number: NCT04356729

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Phase 2

Recruiting

Conditions: Cancer
Tumors
Neoplasms
Neoplasia

Interventions: Drug: Vemurafenib plus Cobimetinib (combination)
Drug: Trastuzumab plus Pertuzumab (combination)
Drug: Alectinib
Drug: Axitinib
Drug: Erlotinib
Drug: Atezolizumab
Drug: Avelumab
Drug: Trastuzumab emtansine
Drug: Vismodegib
Drug: Niraparib

First Posted Date: 2020-04-10

Last Posted Date: 2022-10-26

Lead Sponsor: Ulrik Lassen

Target Recruit Count: 300

Registration Number: NCT04341181

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰
Odense University Hospital, Odense, Denmark

and more 4 locations

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Phase 3

Active, not recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Atezolizumab
Drug: Cabozantinib

First Posted Date: 2020-04-08

Last Posted Date: 2024-10-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 522

Registration Number: NCT04338269

Locations: 🇺🇸
Texas Oncology - Central South, Austin, Texas, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 140 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy